A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Pharmacodynamic Effects of A Single Oral Dose of NDI-010976 in Healthy Adult Subjects
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Firsocostat (Primary)
- Indications Metabolic syndrome; Non-alcoholic steatohepatitis
- Focus Pharmacodynamics
- Sponsors Gilead Sciences
- 17 Apr 2016 Status changed from planning to completed, according to the results presented at The International Liver Congress™ 2016.
- 17 Apr 2016 Results presented at The International Liver Congress 2016
- 24 Apr 2015 New trial record